Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walid F Gellad

Showing results (41-50 of 265) with videos related to

Pageof 27
Sort By:
Drug Safety|January 23, 2016
Maximizing the Post-Approval Safety of Flibanserin: A Role for Regulators, Clinicians, and PatientsSheriza N Baksh, Walid F Gellad, G Caleb Alexander
JAMA|October 22, 2021
A Policy Prescription for Reducing Health Disparities-Achieving PharmacoequityUtibe R Essien, Stacie B Dusetzina, Walid F Gellad
The New England Journal of Medicine|January 3, 2014
Macitentan and pulmonary arterial hypertensionTimothy S Anderson, Chester B Good, Walid F Gellad
JAMA|February 8, 2022
Reducing Health Disparities Through Achieving Pharmacoequity-ReplyUtibe R Essien, Stacie B Dusetzina, Walid F Gellad
JAMA|December 17, 2013
Implications of new insurance coverage for access to care, cost-sharing, and reimbursementA Everette James, Walid F Gellad, Brian A Primack
JAMA|July 7, 2015
Evaluation of Flibanserin: Science and Advocacy at the FDAWalid F Gellad, Kathryn E Flynn, G Caleb Alexander
Journal of General Internal Medicine|September 21, 2007
Race/ethnicity and nonadherence to prescription medications among seniors: results of a national studyWalid F Gellad, Jennifer S Haas, Dana Gelb Safran
JAMA Health Forum|June 16, 2023
Estimated Changes in Insulin Prices and Discounts After Entry of New Insulin Products, 2012-2019Sean Dickson, Nico Gabriel, Walid F Gellad, et al.
JAMA Network Open|June 2, 2021
Trends in the Use of Conventional and New Pharmaceuticals for Hemophilia Treatments Among Medicaid Enrollees, 2005-2020Inmaculada Hernandez, Deanna Rowe, Walid F Gellad, et al.
Medical Care|May 15, 2014
Impact of medicare part D plan features on use of generic drugsYan Tang, Walid F Gellad, Aiju Men, et al.
Pageof 27

Showing results (41-50 of 265) with videos related to

Sort By:
Pageof 27
Drug Safety|January 23, 2016
Maximizing the Post-Approval Safety of Flibanserin: A Role for Regulators, Clinicians, and PatientsSheriza N Baksh, Walid F Gellad, G Caleb Alexander
JAMA|October 22, 2021
A Policy Prescription for Reducing Health Disparities-Achieving PharmacoequityUtibe R Essien, Stacie B Dusetzina, Walid F Gellad
The New England Journal of Medicine|January 3, 2014
Macitentan and pulmonary arterial hypertensionTimothy S Anderson, Chester B Good, Walid F Gellad
JAMA|February 8, 2022
Reducing Health Disparities Through Achieving Pharmacoequity-ReplyUtibe R Essien, Stacie B Dusetzina, Walid F Gellad
JAMA|December 17, 2013
Implications of new insurance coverage for access to care, cost-sharing, and reimbursementA Everette James, Walid F Gellad, Brian A Primack
JAMA|July 7, 2015
Evaluation of Flibanserin: Science and Advocacy at the FDAWalid F Gellad, Kathryn E Flynn, G Caleb Alexander
Journal of General Internal Medicine|September 21, 2007
Race/ethnicity and nonadherence to prescription medications among seniors: results of a national studyWalid F Gellad, Jennifer S Haas, Dana Gelb Safran
JAMA Health Forum|June 16, 2023
Estimated Changes in Insulin Prices and Discounts After Entry of New Insulin Products, 2012-2019Sean Dickson, Nico Gabriel, Walid F Gellad, et al.
JAMA Network Open|June 2, 2021
Trends in the Use of Conventional and New Pharmaceuticals for Hemophilia Treatments Among Medicaid Enrollees, 2005-2020Inmaculada Hernandez, Deanna Rowe, Walid F Gellad, et al.
Medical Care|May 15, 2014
Impact of medicare part D plan features on use of generic drugsYan Tang, Walid F Gellad, Aiju Men, et al.
Pageof 27